Accuracy
Added TRIUMPH-2 dose-level figures to results data table
- ▸TRIUMPH-2 table entry now shows efficacy-estimand results: 4 mg −12.7%, 9 mg −19.1%, 12 mg −20.8% vs. placebo −4.0% at 80 weeks.
- ▸A1C reduction (average 1.6 percentage points) added to TRIUMPH-2 notes.
- ▸TRIUMPH-3 population corrected to include "with or without type 2 diabetes."
- ▸TRIUMPH-3 notes updated to clarify that topline data do not establish cardiovascular-outcome benefit.
SEO / Schema
Removed /fda, /reddit, /search from XML sitemap; fixed Privacy/Terms canonicals
- ▸/fda is a 301 redirect to /fda-regulation — excluded from sitemap per spec.
- ▸/reddit is a 301 redirect to /reddit-observatory — excluded from sitemap per spec.
- ▸/search is noindex,follow — excluded from sitemap per spec.
- ▸Privacy and Terms pages now use hardcoded absolute HTTPS canonicals.
- ▸Added WebPage and BreadcrumbList JSON-LD schema to Privacy and Terms pages.
- ▸Added Open Graph and Twitter meta tags to Privacy and Terms pages.
SEO / Schema
Metadata cleanup — 9 priority pages shortened to 50–65 char titles
- ▸what-is-retatrutide: title 72→65 chars; description 196→162 chars.
- ▸research-grade-retatrutide: title 72→66 chars; description 163→152 chars.
- ▸retatrutide-vs-next-generation-obesity-drugs: title 87→60 chars; description 175→162 chars.
- ▸fake-illicit-retatrutide: title 88→72 chars.
- ▸weight-loss-support: description 176→158 chars.
- ▸clinical-trials: title 72→60 chars; description updated to reflect TRIUMPH-1/2/3 topline status.
- ▸combinations: title 79→68 chars.
Accuracy
Published 8 new original articles
- ▸/retatrutide-gold-rush — Investigation: inside the market for an unapproved drug.
- ▸/retatrutide-powder-vials-reconstitution — Why "reconstitution required" is a warning signal.
- ▸/bacteriostatic-water-shortage-retatrutide — Limited supply vs. confirmed FDA shortage; Rx-only status.
- ▸/amazon-syringes-prescription-peptide-use — Amazon has not banned all syringes; availability depends on classification and state law.
- ▸/triumph-2-retatrutide-results — Dose-level results, A1C findings, and evidence status.
- ▸/triumph-3-retatrutide-results — Weight loss and cardiovascular findings explained.
- ▸/counterfeit-retatrutide-semaglutide-warning — TGA safety alert (September 14, 2026).
- ▸/ohio-retatrutide-clinic-enforcement — Enforcement analysis: Ohio clinic actions.
- ▸All 8 articles include Article/NewsArticle schema, BreadcrumbList schema, AJ Pakpour attribution, published/modified dates, evidence status statements, and 3–6 authoritative citations.
SEO / Schema
Updated internal linking and hub pages for new articles
- ▸TRIUMPH-2 and TRIUMPH-3 articles added to results.tsx RelatedReading.
- ▸Counterfeit warning and Gold Rush articles added to fake-illicit-retatrutide.tsx RelatedReading.
- ▸Gold Rush and Ohio enforcement articles added to online-retatrutide-peptide-sellers.tsx RelatedReading.
- ▸All 8 articles added to guides.tsx with new Investigations and Evidence categories.
- ▸All 8 articles added to seo-routes.ts with priority 0.8–0.9 and lastmod 2026-09-16.
Accuracy
TRIUMPH Phase 3 results and Lilly 5-study status updated sitewide
- ▸Added TRIUMPH-2 topline results (up to 20.8% weight loss at 80 weeks, announced July 23, 2026) across all relevant pages.
- ▸Added TRIUMPH-3 topline results (up to 22.6% weight loss at 80 weeks, announced July 23, 2026) across all relevant pages.
- ▸Updated Eli Lilly status to reflect five positive Phase 3 studies and stated intent to support global submissions for obesity, knee osteoarthritis pain, and obstructive sleep apnea.
- ▸Corrected news.tsx status panel: TRIUMPH-1/2/3 topline reported; TRIUMPH-CVOT ongoing.
- ▸Corrected results.tsx Phase 3 status label to reflect TRIUMPH-1/2/3 topline completion.
- ▸Corrected news.tsx FAQ answers that incorrectly stated TRIUMPH-2 was still ongoing after July 23, 2026 topline announcement.
- ▸Confirmed canonical efficacy figures: 28.3% (12 mg), 25.9% (9 mg), 19.0% (4 mg) at 80 weeks; 30.3% extension at 104 weeks.
- ▸TRIUMPH-1 24.2%/48wks correctly labeled as Phase 2 throughout.
Accuracy
Removed all boxed-warning language applied to retatrutide
- ▸Retatrutide is investigational and has no FDA-approved prescribing label; it cannot carry a "boxed warning."
- ▸Corrected faq.tsx JSON-LD answer: replaced "carries a precautionary boxed warning" with accurate class-level MTC/MEN2 precaution language.
- ▸Corrected retatrutide-vs-semaglutide.tsx comparison table: retatrutide now reads "Class-level MTC/MEN2 precaution (investigational; no approved label)" vs. semaglutide's accurate "FDA boxed warning."
- ▸Corrected guides.tsx card description: "MTC/MEN2 boxed warning" replaced with "MTC/MEN2 precautions."
- ▸Glossary MTC entry retained accurate language: "GLP-1 receptor agonists carry a boxed warning" (true for approved drugs in the class).
Accuracy
Corrected 503A/503B legal explanations
- ▸Clarified that 503A pharmacies compound for individual patients with a valid prescription; they do not compound retatrutide for office stock or general sale.
- ▸Clarified that 503B outsourcing facilities may produce larger batches but are subject to FDA registration, cGMP, and cannot compound copies of commercially available drugs.
- ▸Removed any language suggesting either pathway is a legal route to obtain retatrutide outside of clinical trials.
Accuracy
Added September 14, 2026 TGA safety alert
- ▸Added TGA (Australian Therapeutic Goods Administration) safety alert to news.tsx: product sold as retatrutide contained no retatrutide; contained undeclared semaglutide at approximately 8× normal level.
- ▸Consumer experienced uncontrollable vomiting and a torn esophagus requiring hospital treatment.
- ▸Alert correctly scoped to Australian TGA investigation; noted U.S. FDA has not issued a parallel alert.
- ▸Cross-referenced from fake-illicit-retatrutide.tsx and online-retatrutide-peptide-sellers.tsx.
SEO / Schema
Fixed duplicate canonical tags and duplicate schema
- ▸Removed canonical tag from RootLayout.tsx — it was emitting a generic "/" canonical on every page, overriding per-page canonicals.
- ▸Removed Organization and WebSite schema from RootLayout.tsx — these were duplicating the per-page @graph blocks.
- ▸RootLayout now emits only the site-wide default title and meta description as fallbacks.
- ▸Per-page Helmet blocks are now the sole source of canonical, OG, and JSON-LD on every route.
- ▸Eliminated duplicate BreadcrumbList schema that was being emitted by both the Breadcrumb component and page-level JSON-LD on some pages.
SEO / Schema
Fixed AJ Pakpour ProfilePage schema
- ▸Corrected @type to "ProfilePage" with a nested "mainEntity" Person node.
- ▸sameAs array contains only ["https://ajpakpour.com"] — no unverified social profiles.
- ▸Removed any medicalReviewer, reviewedBy, or MedicalWebPage schema sitewide.
- ▸Role consistently stated as "Founder & Publisher, TryTrutide" across sitemap, explore, and search pages.
SEO / Schema
Improved titles and meta descriptions; fixed /research breadcrumb and indexing
- ▸Audited all page titles: target 50–65 characters, include brand name, descriptive keyword.
- ▸Audited all meta descriptions: target 145–165 characters, include primary keyword and value proposition.
- ▸Added breadcrumb component to /research index page.
- ▸/search page confirmed noindex,follow — correct for a dynamic search UI.
- ▸/sitemap page confirmed noindex,follow — correct for a UI sitemap.
- ▸Server-side 301 redirects confirmed: /fda → /fda-regulation, /reddit → /reddit-observatory.
UX / Accessibility
Fixed physician questionnaire accessibility and form semantics
- ▸All form inputs now have associated <label> elements with matching htmlFor/id pairs.
- ▸Error messages use role="alert" for screen reader announcement.
- ▸Yes/No safety question buttons use aria-pressed for state communication.
- ▸Step navigation buttons meet 44px minimum touch target height.
- ▸Duplicate-submission guard prevents double-posting on slow connections.
- ▸Honeypot field added for spam filtering.
Legal
Rewrote privacy policy to match actual site practices
- ▸Privacy policy now accurately describes data collected: physician review form submissions, contact form submissions, and standard server logs.
- ▸Removed references to data practices not in use (advertising pixels, third-party data brokers).
- ▸Added explicit section on physician review form data handling and recipient (rx@connectscripts.com).
- ▸Updated /privacy and /terms metadata: OG tags, schema (WebPage), and breadcrumbs.
Technical
Fixed HEAD request returning 404; replaced broken external links
- ▸Added HEAD handler in src/server/entry.ts: HEAD requests for valid public pages now return 200 with correct headers instead of 404.
- ▸Audited all external links sitewide; replaced confirmed broken URLs with current equivalents or removed them.
- ▸ClinicalTrials.gov search links updated to current URL format.
- ▸FDA Drugs@FDA link verified active.
UX / Accessibility
Mobile/responsive QA pass
- ▸Homepage status panel: converted from fragile flex-with-manual-borders to auto-fit grid; border logic no longer breaks on single-column mobile.
- ▸Research article cards, framework quadrants, and directory hub cards: removed hardcoded borderRight logic that assumed a fixed column count; replaced with uniform borderBottom.
- ▸Hero section padding: converted to clamp() for graceful scaling from 375px up.
- ▸Hero text container: added width: 100% to prevent overflow on narrow viewports.
- ▸Footer brand column: removed minWidth: 180px override that could fight the auto-fit grid.
- ▸Global CSS: added @media (max-width: 360px) rule tightening horizontal padding to 1rem on very small screens.
SEO / Schema
Updated dateModified to 2026-09-16 on all changed pages
- ▸All pages modified during this correction pass have dateModified set to 2026-09-16 in their WebPage JSON-LD.
- ▸reddit-observatory.tsx dateModified corrected from 2026-09-13 to 2026-09-16.
